PatentVest Report Highlights IP Gaps in Oral GLP-1 Drug Race
Event summary
- PatentVest analyzed 1,200+ patents across 26 clinical-stage oral GLP-1 programs, revealing significant IP defensibility disparities.
- $47B in GLP-1-related deal value committed since 2023, yet most oral programs remain unpartnered.
- Semaglutide and tirzepatide patents set to expire in 2031 and 2036, respectively, creating exclusivity pressure.
- 50 oral small-molecule GLP-1 programs identified, with 30 in clinical development.
The big picture
The $71B injectable GLP-1 market has barely scratched the surface, with less than 5% of eligible patients treated. Oral small-molecule alternatives are converging on 12–16% weight-loss efficacy, making patent defensibility the key differentiator. As the patent cliff approaches for leading injectables, the race to secure exclusivity will intensify, reshaping the competitive landscape.
What we're watching
- Patent Defensibility
- How IP portfolio strength will determine long-term market positioning as clinical efficacy converges.
- Exclusivity Pressure
- Whether oral GLP-1 programs can secure sufficient patent protection before semaglutide and tirzepatide patents expire.
- Deal Activity
- The pace at which unpartnered oral GLP-1 programs attract strategic investments or partnerships.
Related topics